Philip J Saylor
Overview
Explore the profile of Philip J Saylor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Machacek M, Wang H, Devins K, Sadow P, Wu C, Oliva E, et al.
Am J Surg Pathol
. 2025 Jan;
49(2):113-120.
PMID: 39774140
Staging of renal pelvic urothelial carcinoma can be challenging due to anatomic variation at the renal pelvis compared with ureter and bladder and calls into question the prognostic accuracy of...
2.
Cochran R, Saylor P, Ghoshhajra B, Harisinghani M
Radiol Imaging Cancer
. 2024 Aug;
6(5):e240116.
PMID: 39212525
No abstract available.
3.
Coen J, Rodgers J, Saylor P, Lee C, Wu C, Parker W, et al.
Int J Radiat Oncol Biol Phys
. 2024 Aug;
121(1):153-161.
PMID: 39147209
Purpose: For bladder-sparing treatment of muscle-invasive bladder cancer, 5-fluorouracil/cisplatin with twice-daily radiation (FCT) or gemcitabine plus daily radiation (GD) are effective chemoradiation (CRT) regimens. This trial evaluated these regimens and...
4.
Churchill T, Smith M, Michaelson M, Lee R, Guseh J, Wasfy M, et al.
J Am Soc Echocardiogr
. 2024 Mar;
37(7):706-708.
PMID: 38499230
No abstract available.
5.
Mei S, Alchahin A, Embaie B, Gavriliuc I, Verhoeven B, Zhao T, et al.
JCI Insight
. 2024 Feb;
9(6).
PMID: 38358826
Neuroblastoma is an aggressive pediatric cancer with a high rate of metastasis to the BM. Despite intensive treatments including high-dose chemotherapy, the overall survival rate for children with metastatic neuroblastoma...
6.
Saylor P, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300230.
PMID: 38354328
Purpose: Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant biomarkers are lacking. We evaluated automated bone scan index...
7.
Mei S, Alchahin A, Tsea I, Kfoury Y, Hirz T, Jeffries N, et al.
Genome Med
. 2024 Jan;
16(1):1.
PMID: 38281962
Background: Despite therapeutic advances, once a cancer has metastasized to the bone, it represents a highly morbid and lethal disease. One third of patients with advanced clear cell renal cell...
8.
Saylor P, Kozin S, Matsui A, Goldberg S, Aoki S, Shigeta K, et al.
Radiother Oncol
. 2024 Jan;
192:110091.
PMID: 38224917
Background & Purpose: Radium-223 (Ra223) improves survival in metastatic prostate cancer (mPC), but its impact on systemic immunity is unclear, and biomarkers of response are lacking. We examined markers of...
9.
Kamran S, Zhou Y, Otani K, Drumm M, Otani Y, Wu S, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5116-5127.
PMID: 37870965
Purpose: There is an urgent need for biomarkers of radiation response in organ-sparing therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral tumor resection followed by chemoradiation, is an...
10.
Zlotta A, Ballas L, Niemierko A, Lajkosz K, Kuk C, Miranda G, et al.
Lancet Oncol
. 2023 May;
24(6):669-681.
PMID: 37187202
Background: Previous randomised controlled trials comparing bladder preservation with radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual. Given that no further trials are foreseen, we aimed to...